Samil Pharmaceutical Co.,Ltd reported earnings results for the third quarter and nine months ended September 30, 2022. For the third quarter, the company reported sales was KRW 1,070.32 million compared to KRW 549.42 million a year ago. Net loss was KRW 1,920.48 million compared to KRW 1,671.46 million a year ago. Basic loss per share from continuing operations was KRW 138.1818 compared to KRW 120 a year ago. Diluted loss per share from continuing operations was KRW 138.1818 compared to KRW 120 a year ago. Basic loss per share was KRW 138.1818 compared to KRW 120 a year ago.
For the nine months, sales was KRW 2,960.54 million compared to KRW 1,476.95 million a year ago. Net loss was KRW 1,858.78 million compared to KRW 2,216.3 million a year ago. Basic loss per share from continuing operations was KRW 134.5455 compared to KRW 160.9091 a year ago. Diluted loss per share from continuing operations was KRW 134.5455 compared to KRW 160.9091 a year ago. Basic loss per share was KRW 134.5455 compared to KRW 160.9091 a year ago.